Hong Kong-based AI-driven company sells potential breast cancer drug in deal whose value could exceed US$500 million

Source: Tech – South China Morning PostStemline Therapeutics, a wholly-owned unit of Menarini Group, will make a US$12 million upfront payment to Insilico under the agreement, which will be followed by sales royalties worth up to ‘double digits’.Read More